China Daily Briefing

China holiday travel data is spiking, and global funds are repositioning — SCMP's 5-figure investor watch highlights the combination of strong Golden Week volume, PBOC's yuan management stance, and Northbound/Southbound Stock Connect flows as the week's market drivers. The Travel sector's +2.48% Friday reflects partial positioning; the full post-holiday data flow next week will either confirm or complicate the consumer-spending thesis.

Chinese state funds are increasing exposure to Hua Hong Semiconductor, doubling down on the legacy chip push as Beijing accelerates domestic semiconductor self-sufficiency. This is PBOC-adjacent capital deployment at scale — it tells you the SOE mandate is to build the supply chain regardless of near-term margin, and Hua Hong's A/H share premium is now a policy instrument, not just a market signal. STAR Market names with legacy chip exposure are the related trade.

China's pharma policy push to cultivate five innovative drugs with more than US$1 billion in global returns by 2030 is a structural signal for the biotech/pharma sector — it frames state-directed R&D investment as a market driver, not just a policy aspiration. Education +2.57% and consumer sectors rising in tandem with the pharma narrative tells you investors are pricing a broader domestic demand recovery, not just the Golden Week sugar rush.